Corline Biomedical AB (STO:CLBIO)

Market Cap	484.92M
Revenue (ttm)	10.02M
Net Income (ttm)	-23.49M
Shares Out	24.49M
EPS (ttm)	-1.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,718
Average Volume	91,390
Open	20.00
Previous Close	19.90
Day's Range	19.20 - 20.00
52-Week Range	5.98 - 27.20
Beta	0.35
RSI	55.75
Earnings Date	Nov 7, 2025

About Corline Biomedical AB

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company’s products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CLBIO

Financial Performance

In 2024, Corline Biomedical AB's revenue was 17.27 million, a decrease of -51.37% compared to the previous year's 35.52 million. Losses were -23.19 million, 1182.1% more than in 2023.